Recently, the U.S. patent application "Antibody targeting IL-13RA2 and use thereof" — a global counterpart patent application filed and owned by CARsgen Therapeutics and Clergy Medicine, with the theme "Antibody Targeting IL-13RA2 and Its Application" — has been granted. Previously, five invention patents in this same family had been granted in Japan, Australia, New Zealand, Russia, and Taiwan, China.

Beijing Caihe Law Firm was entrusted by CARsgen Therapeutics and Clergy Medicine to provide full-cycle consulting services for this series of counterpart patent applications, including selecting foreign firms, preparing documents, and responding to office actions. CARsgen Therapeutics is a biopharmaceutical company operating in China and the United States, focusing primarily on innovative CAR-T cell therapies for the treatment of hematological malignancies and solid tumors. CARsgen Therapeutics' product pipeline includes an upgraded fully human BCMA-targeting CAR-T, the world's only Claudin18.2 CAR-T with potential first-in-class globally that has obtained IND clinical trial approval, and a GPC3 CAR-T with potential first-in-class globally.